SCHEDULE: FMR LLC Reduces Prime Medicine Stake Below 5%
Beneficial Ownership Report (Schedule 13G Amendment)
FMR LLC and Abigail P. Johnson have reduced their beneficial ownership in Prime Medicine Inc. to 3.8% of common stock.
Summary
- FMR LLC and Abigail P. Johnson filed an Amendment No. 4 to Schedule 13G, reporting their beneficial ownership in Prime Medicine Inc. common stock.
- As of September 30, 2025, the aggregate beneficial ownership for each reporting person is 6,731,796 shares.
- This represents 3.8% of the total outstanding common stock of Prime Medicine Inc.
- FMR LLC holds sole voting power over 6,724,867 shares and sole dispositive power over 6,731,796 shares.
- Abigail P. Johnson holds sole dispositive power over 6,731,796 shares.
- The filing explicitly states that the ownership is now 5 percent or less of the class, indicating a reduction from a previously higher stake.
- The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to a significant institutional investor reducing its stake below the 5% reporting threshold, which can be interpreted as a decrease in confidence or a reallocation of assets.
Positives
- NA
Negatives
- FMR LLC and Abigail P. Johnson have reduced their beneficial ownership in Prime Medicine Inc. to 3.8%, falling below the 5% reporting threshold. This reduction by a significant institutional investor may be interpreted as a decrease in conviction or exposure.
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This filing indicates a change in the investment position of a major institutional investor within the biotechnology or pharmaceutical sector, where Prime Medicine Inc. operates. A reduction in a significant institutional stake can sometimes signal a shift in investor sentiment towards the company or the broader industry, though the specific reasons for such a change are not disclosed in this type of regulatory filing.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: The reduction in a significant institutional stake may lead to concerns about investor confidence and potentially influence the stock price.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires the filing of this statement, reflecting the beneficial ownership as of this date. |
| 11/04/2025 | Signature date of the Schedule 13G Amendment No. 4 by FMR LLC and Abigail P. Johnson. |
Recommendation
holdThe reduction of FMR LLC's stake in Prime Medicine Inc. below the 5% threshold, as indicated by this Schedule 13G Amendment, suggests a decreased conviction or a strategic reallocation by a major institutional investor. While not a complete divestment, this move typically signals a less favorable outlook from the reporting entity. Investors should 'hold' and monitor future filings and company performance for clearer directional signals, as this reduction could exert downward pressure or reflect underlying concerns not detailed in this filing.
Keywords
Prime Medicine Inc., FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.